<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01135667</url>
  </required_header>
  <id_info>
    <org_study_id>TAILOR</org_study_id>
    <nct_id>NCT01135667</nct_id>
  </id_info>
  <brief_title>Prasugrel Versus Double Dose Clopidogrel to Treat Clopidogrel Low-responsiveness After PCI</brief_title>
  <acronym>TAILOR</acronym>
  <official_title>Thrombocytes And IndividuaLization of ORal Antiplatelet Treatment After Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lene Holmvang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      All patients undergoing elective or sub-acute PCI are screened by MULTIPLATE test for
      clopidogrel low-responsiveness after receiving 600 mg clopidogrel the day before.

      A cut off value has previously been established. Only low-responders with Multiplate values
      above the cut off value are included in the study. The patients are randomized to either
      clopidogrel 150 mg once daily or Prasugrel 10 mg (age &gt; 75 og bodyweight &lt; 60 kg 5 mg)once
      daily for 30 days after the procedure.

      Follow up will be at 30 days after PCI were another MULTIPLATE test will be performed.

      Primary endpoint:Platelet inhibition (by MULTIPLATE) after 30 days of intensified
      antiplatelet therapy.

      Clinical endpoints such as bleeding complications (GUSTO, TIMI) during treatment, and major
      adverse cardiac events (MACE) at 30 days will be collected and reported but the study size
      does not allow for formal statistical analysis The study ends by the 30 days follow up visit
      and all patients continue with clopidogrel 75 mg once daily for another 11 months (not study
      related)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Heparin ADP by Multiplate</measure>
    <time_frame>30 days</time_frame>
    <description>Test of platelet inhibition (ADP receptor mediated) after 30 days of intensifiet anti platelet therapy</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <condition>Acute Coronary Syndromes</condition>
  <arm_group>
    <arm_group_label>clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>clopidogrel 150 mg once daily for 30 days (and then 75 mg for additional 11 months - not study related)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prasugrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prasugrel 10 mg once daily for 30 days (and then clopidogrel 75 mg once daily for additional 11 months - not study related)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
    <description>clopidogrel 150 mg once daily for 30 days</description>
    <arm_group_label>clopidogrel</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel 10 mg</intervention_name>
    <description>Prasugrel 10 mg once daily for 30 days</description>
    <arm_group_label>Prasugrel</arm_group_label>
    <other_name>Efient</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PCI with stenting and Multiplate hep-ADP &gt; 70 U despite clopidogrel loading

        Exclusion Criteria:

          -  need for vit K antagonist

          -  women with childbearing potential

          -  breastfeeding women

          -  Planned surgery within 6 months

          -  Intolerance to clopidogrel, prasugrel or aspirin

          -  previous stroke
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lene Holmvang, MD</last_name>
    <role>Study Director</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet, Department of Cardiology, 2013</name>
      <address>
        <city>Copenhagen O</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2010</study_first_submitted>
  <study_first_submitted_qc>June 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2010</study_first_posted>
  <last_update_submitted>October 3, 2012</last_update_submitted>
  <last_update_submitted_qc>October 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Lene Holmvang</investigator_full_name>
    <investigator_title>MD DMSc</investigator_title>
  </responsible_party>
  <keyword>clopidogrel</keyword>
  <keyword>prasugrel</keyword>
  <keyword>low responder</keyword>
  <keyword>multiplate</keyword>
  <keyword>verify now</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

